Trial reportNature communications2024
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
2 registry-linked trialsOpen access · goldAbstract readMulticenter StudyClinical Trial, Phase II
In one paragraph
Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
A Prospective Clinical Study to Evaluate the Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
Who cites it
24 citing papers in PubMed, 22 citations in OpenAlex.
- Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.Blood advances · 2025Trial
- A 38-color spectral panel for cost efficient characterization of T cell therapy products.Cytotherapy · 2026Article
- Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT.Reviews in medical virology · 2026Review
- Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.Molecular therapy. Advances · 2026Review
- New Insights Into Factors Shaping CMV-Specific T-Cell Polyfunctionality After Hematopoietic Cell Transplantation.American journal of hematology · 2026Article
- A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures.Nature communications · 2026Article
- Human leukocyte antigen genotype modulates cytomegalovirus- and Epstein-Barr virus-specific T-cell response in healthy donors for optimized virus-specific T-cell donor selection.Frontiers in immunology · 2026Article
- Innovation in active and passive immunisation of people who are immunocompromised: a call to action.The Lancet. Infectious diseases · 2026Review
- Boosting the Predictive Power of Virus-Specific T-Cell Clinical Trials via Generative Models.Computational and structural biotechnology journal · 2026Article
- Changing scenario in prevention and management of CMV infections in pediatric hematopoietic stem cell transplant patients.Bone marrow transplantation · 2026Review
- Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies.Frontiers in immunology · 2026Review
- Comprehensive management of hematopoietic stem cell transplantation complications: from infection prevention to immune microenvironment reconstruction.Frontiers in immunology · 2026Review
- Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025Review
- Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.Blood advances · 2025Review
- Virus-Specific T-Cell Therapy for Prophylaxis and Treatment of Cytomegalovirus Infections After Transplantation: a Scoping Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors.Cancers · 2025Review
- T cell receptor-like antibody specifically targets and eliminates cells infected with cytomegalovirus.Journal of translational medicine · 2025Article
- Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?Viruses · 2025Review
- "Attack!" Cellular Therapies to Attack Pathogens and Tumors.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Article
- Immunological pathogenesis and treatment progress of adenovirus pneumonia in children.Italian journal of pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors at 20 institutions in 1 country.
Michael D KellerCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0001-8323-3085
Patrick J HanleyCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Yueh-Yun ChiDepartment of Pediatrics and Preventative Medicine, University of Southern California, Los Angeles, CA, USA.
Paibel Aguayo-HiraldoCancer and blood disease institute, Children's Hospital of Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-0196-806X
Christopher C DvorakDivision of Pediatric Allergy, Immunology, and BMT, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6146-3952
Michael R VernerisDepartment of Pediatrics and Division of Child's Cancer and Blood Disorders, Children's Hospital Colorado and University of Colorado, Denver, CO, USA.
Donald B KohnDepartment of Microbiology, Immunology & Molecular Genetics and Department of Pediatrics David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Sung-Yun PaiImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-0158-8147
Blachy J Dávila SaldañaCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Benjamin HanischDivision of Pediatric Infectious Diseases, Children's National Hospital, Washington, DC, USA.
Troy C QuiggPediatric Blood & Bone Marrow Transplant and Cellular Therapy, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.ORCID http://orcid.org/0000-0002-5268-7938
Roberta H AdamsCenter for Cancer and Blood Disorders, Phoenix Children's/Mayo Clinic Arizona, Phoenix, AZ, USA.
Ann DahlbergClinical Research Division, Fred Hutch Cancer Center/Seattle Children's Hospital/University of Washington, Seattle, WA, USA.
Shanmuganathan ChandrakasanAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8007-9932
Hasibul HasanCancer and blood disease institute, Children's Hospital of Los Angeles, Los Angeles, CA, USA.
Jemily MalvarCancer and blood disease institute, Children's Hospital of Los Angeles, Los Angeles, CA, USA.
Mariah A Jensen-WachspressCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Christopher A LazarskiCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0001-8917-7280
Gelina SaniCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
John M IdsoCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Haili LangCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Pamela ChanskyCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0002-8169-992X
Chase D McCannCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Jay TannaCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Allistair A AbrahamCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Jennifer L WebbCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Abeer ShibliCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.
Amy K KeatingPediatric Stem Cell Transplant, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA, USA.
Prakash SatwaniDivision of Pediatric Hematology/Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, NY, USA.
Pawel MuranskiDivision of Pediatric Hematology/Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, NY, USA.
Erin HallDivision of Pediatric Hematology/Oncology/Bone Marrow Transplant, Children's Mercy Kansas City, Kansas City, MO, USA.
Michael J EckrichPediatric Transplant and Cellular Therapy, Levine Children's Hospital, Wake Forest School of Medicine, Charlotte, NC, USA.
Evan ShereckDivision of Hematology and Oncology, Oregon Health & Science Univ, Portland, OR, USA.
Holly MillerCenter for Cancer and Blood Disorders, Phoenix Children's/Mayo Clinic Arizona, Phoenix, AZ, USA.
Ewelina MamcarzDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
Rajni AgarwalDivision of Pediatric Hematology/Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University, Palo Alto, CA, USA.
Satiro N De OliveiraDivision of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8181-7316
Mark T Vander LugtDivision of Pediatric Hematology/Oncology/BMT, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI, USA.
Christen L EbensDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, University of Minnesota MHealth Fairview Masonic Children's Hospital, Minneapolis, MI, USA.
Victor M AquinoDivision of Pediatric Hematology/Oncology, University of Texas, Southwestern Medical Center Dallas, Dallas, TX, USA.
Jeffrey J BednarskiDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0001-6902-0876
Julia ChuDivision of Pediatric Allergy, Immunology, and BMT, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0009-0000-2710-7244
Suhag ParikhAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Jennifer WhangboCancer and Blood Disorders Center, Dana Farber Institute and Boston Children's Hospital, Boston, MA, USA.
Michail LionakisLaboratory of Clinical Immunology & Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-4994-9500
Elias T ZambidisPediatric Blood and Marrow Transplantation Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elizabeth GourdineCancer and blood disease institute, Children's Hospital of Los Angeles, Los Angeles, CA, USA.
Catherine M BollardCenter for Cancer & Immunology Research, Children's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0001-5140-9090
Michael A PulsipherDivision of Pediatric Hematology/Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT, USA. michael.pulsipher@hci.utah.edu.
Children's National · USChildren's Hospital of Los Angeles · USAflac (United States) · USBoston Children's Hospital · USCenter for Cancer and Blood Disorders · USColumbia University Irving Medical Center · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · USChildren's Hospital Colorado · USChildren's Mercy Hospital · USHelen DeVos Children's Hospital · USIntermountain Healthcare · USJohns Hopkins University · USLevine Children's Hospital · USNational Cancer Institute · USNational Institute of Allergy and Infectious Diseases · USOregon Health & Science University · USSeattle Children's Hospital · USStanford University · USSt. Jude Children's Research Hospital · US
Funding
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9MImmunopathogenesis of Fungal InfectionsZIAAI001175 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LIONAKIS, MICHAIL · 2012 to 2025
$23.9MRandomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5MInstitutional Career Development CoreKL2TR002492 · NCATS · UNIVERSITY OF MINNESOTA · PI INGBAR, DAVID H · 2018 to 2022
$6.3MChildren’s National Stimulating Access to Research in Residency (CNStARR) Program (NHLBI)R38HL167247 · NHLBI · CHILDREN'S RESEARCH INSTITUTE · PI Andrea Leigh Hahn · 2023 to 2026
$1.7MUnrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant ConsortiumUG1HL069254 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S · 2017 to 2023
$1.3MNCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR002494NHLBI NIH HHS R38 HL167247NHLBI NIH HHS UG1 HL069254NIAID NIH HHS U01 AI126612
Abstract
Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed a phase II multicenter study (NCT03475212) for the treatment of pediatric patients with inborn errors of immunity and/or post allogeneic hematopoietic stem cell transplant with refractory viral infections using partially-HLA matched VSTs targeting cytomegalovirus, Epstein-Barr virus, or adenovirus. Primary endpoints were feasibility, safety, and clinical responses (>1 log reduction in viremia at 28 days). Secondary endpoints were reconstitution of antiviral immunity and persistence of the infused VSTs. Suitable VST products were identified for 75 of 77 clinical queries. Clinical responses were achieved in 29 of 47 (62%) of patients post-HSCT including 73% of patients evaluable at 1-month post-infusion, meeting the primary efficacy endpoint (>52%). Secondary graft rejection occurred in one child following VST infusion as described in a companion article. Corticosteroids, graft-versus-host disease, transplant-associated thrombotic microangiopathy, and eculizumab treatment correlated with poor response, while uptrending absolute lymphocyte and CD8 T cell counts correlated with good response. This study highlights key clinical factors that impact response to VSTs and demonstrates the feasibility and efficacy of this therapy in pediatric HSCT.
Indexed as
Epstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationVirus DiseasesChildHerpesvirus 4, HumanHumansRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03475212ClinicalTrials.gov
NCT07685457ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.